Dextromethorphan/bupropion
| Combination of | |
|---|---|
| Dextromethorphan | NMDA receptor antagonist, σ1 receptor agonist, serotonin–norepinephrine reuptake inhibitor |
| Bupropion | Norepinephrine–dopamine reuptake inhibitor, CYP2D6 inhibitor |
| Clinical data | |
| Trade names | Auvelity |
| Other names | DXM/BUP; AXS-05 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Dextromethorphan/bupropion, sold under the brand name Auvelity, is a combination medication for the treatment of major depressive disorder (MDD) and agitation associated with dementia due to Alzheimer's disease. Its active components are dextromethorphan (DXM) and bupropion. It is taken as a tablet by mouth.
Side effects of dextromethorphan/bupropion include dizziness, headache, diarrhea, somnolence, dry mouth, sexual dysfunction, and hyperhidrosis, among others. The mechanism of action of dextromethorphan/bupropion in the treatment of depression is unknown.
Dextromethorphan/bupropion was developed by Axsome Therapeutics and was approved for the treatment of major depressive disorder in the United States in August 2022.